Beta-adrenergic receptor antagonists, also known as beta-blockers, work by competitively binding to beta-adrenergic receptors on target cells. This binding prevents the activation of these receptors by endogenous catecholamines such as epinephrine and norepinephrine. Consequently, beta-blockers reduce the effects of sympathetic stimulation, leading to decreased heart rate, reduced contractility, and lowered blood pressure. These are used in hypertension, arrhythmia, diabetic macular edema, asthma, glaucoma, and other diseases. An increase in the prevalence of hypertension and glaucoma is expected to boost the beta-adrenergic receptor antagonist revenue over the forecast years. For instance, according to WHO, in the USA, around 3 million people have glaucoma and out of this population, 50 percent don’t know they have the disease. Companies such as Abbvie, Novartis, Eli Lilly, Senju, ACG Biologics, Baxter Healthcare, Chong Kun Dang, Ligand, Novelion, Otsuka, Santen, Whitecap Biosci, Sophia Laboratories currently provide treatment for hypertension, arrhythmia, glaucoma, and many related diseases. Visken is one of the prominent drugs by AbbVie which is being used to treat high blood pressure and prevent strokes, heart attacks, and kidney problems. Apart from that, in the parenteral segment, Helios ocular insert by AbbVie is extensively used in the treatment of glaucoma. Moreover, many companies are coming up with new molecules in this space. For instance, Novelion is one such company that is currently conducting a clinical trial of the drug QLT091568 for the treatment of glaucoma, ocular hypertension, and pigment-dispersion syndrome.
Key Developments
In June 2022, Eagle Pharmaceuticals announces the submission of NDA to the US FDA for Landiolol, a beta-1 adrenergic blocker.
Approved Drug Molecules for Beta-Adrenergic Receptor Antagonist
Carvedilol Sustained Release (Dilatrend SR)
Brimonidine/Timolol (Bimatoprost)
Brimonidine Tartrate/ Timolol Maleate (Combigan)
Pindolol (Visken)
Tafluprost/Timolol (Taptiqom)
Carteolol/Latanoprost (Mikeluna)
Drugs under the Pipeline for Beta-Adrenergic Receptor Antagonist
QLT091568(Novelion)- Phase- I
PRO-122( Sophia Laboratories)- Phase III/IV
WB007(Whitecap Biosci)- Phase-I/II
Clinical Activity and Development of Beta-Adrenergic Receptor Antagonist
In the beta-adrenergic receptor antagonist space, approximately 15 companies are focusing on 307 disease indications and right now about 162 clinical trials are being conducted in this category of drugs. For instance,
As of June 2023, Amgen is currently conducting a Phase 1, open-label drug-drug interaction study to investigate the effect of Rocatinlimab(AMG 451) on the pharmacokinetics of multiple CYP450 substrates(such as metoprolol and carvedilol) in patients with moderate to severe atopic dermatitis.
As of May 2023, Menarini is recruiting for an open-label, multicenter, multinational, interventional phase IV clinical trial to assess the efficacy and safety of the extemporaneous combination of Nebivolol and Ramipril in hypertensive patients- Artemisia study.
Target Indication Analysis of Beta-Adrenergic Receptor Antagonist
The beta-adrenergic receptor blocker is used in the treatment of hypertension, arrhythmia, diabetic macular edema, asthma, glaucoma, and other diseases. According to the World Health Organization, there are more than 700 million people with untreated hypertension and over one billion people with hypertension (82% of all people with hypertension in the world) lived in low- and middle-income countries. Primarily, Beta-adrenergic receptor antagonists are extensively used in the treatment of eye diseases. For instance, Bimatoprost is one drug by Abbvie which is used to treat Glaucoma and drain the ocular fluid thereby reducing the intraocular pressure. In the treatment of heart failure and high blood pressure, beta-adrenergic receptor antagonists such as Dilatrend SR are used widely. Through research and development, the indications in which beta-adrenergic receptor antagonists can be used are getting expanded. For instance, according to a PubMed publication of March 2020, among all beta blockers, long-term atenolol use is associated with reduced prostate cancer-specific mortality.
Regional Analysis of Beta-Adrenergic Receptor Antagonist
Beta-Adrenergic Receptor Antagonist Market
North America has the largest market share among all regions. Major countries such as the United States, and Canada are key contributors to this market. In the year 2022, AbbVie reported revenue of $74 million for Combigan in the USA. Factors such as research and development advancements, favorable reimbursement policies, a growing aging population, and an increase in the prevalence of hypertension are majorly driving the market growth. For instance, in the USA, nearly half of the adults have hypertension (119.9 million) and about 1 out of 4 adults with hypertension have their hypertension under control. The prevalence of hypertension in Germany is 55%, which is twice the rate in Canada and the USA, and this accounts for 26% of total mortality in Germany. Moreover, primary open-angle glaucoma (POAG) is responsible for 12.3% of blindness worldwide. The Asia Pacific beta-adrenergic receptor antagonists market witnessed the highest growth in recent years. Major countries driving this market include China, Japan, South Korea, India, and Australia. The increasing prevalence of cardiovascular diseases and the rising geriatric population, advancements in healthcare infrastructure, growing awareness about cardiovascular health, and the availability of innovative beta blockers fuel the market growth in the future. With a focus on improving patient outcomes and managing chronic conditions in the Asia Pacific region presents a promising market for beta-adrenergic receptor antagonists.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
The approved molecules of beta-adrenergic receptor antagonists are Propranolol, Carvedilol, Dorzolamide, Betaxolol hydrochloride, Bimaprost, Nebivolol
The global industry of beta-adrenergic receptor antagonists is valued at 5,634.8 Mn in 2022.
The major players in this space are Abbvie, Novartis, Eli Lilly, Senju, ACG Biologics, Baxter Healthcare, Chong Kun Dang, Ligand, Novelion, Otsuka, Santen, Whitecap Biosci, Sophia Laboratories.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- AbbVie
- Novartis
- Eli Lilly
- Senju
- ACG Biologics
- Baxter Healthcare
- Chong Kun Dang
- Ligand
- Novelion
- Otsuka
- Santen
- Whitecap Biosci
- Sophia Laboratories